A Market in Motion: €1.5 Billion as Europe’s Milestone
Market research firm Prohibition Partners projects Europe’s legal medical cannabis market will exceed €1.5 billion in 2026. Just years ago, Europe was regarded as a cautious latecomer—today it’s contested terrain for international producers, institutional investors, and pharmaceutical companies. Germany drives this growth disproportionately: 62 percent of all Canadian cannabis flower exports recently went to Germany—a 763 percent increase versus 2024. Last year alone, Germany crossed the 200-ton threshold for medical cannabis imports. For the industry, surpassing the €1.5 billion mark signals a strategic inflection: it attracts new capital sources and fundamentally shifts competitive dynamics.
📑 Inhaltsverzeichnis
- A Market in Motion: €1.5 Billion as Europe’s Milestone
- Germany as Regulatory Anchor—With Unresolved Questions
- New Focus Areas: Women’s Health, Portugal, and the End of Flower?
- From Flower to Pharmaceutical: The Strategic Question Behind All Questions
- Frequently Asked Questions
- 💬 Fragen? Frag den Hanf-Buddy!
Germany as Regulatory Anchor—With Unresolved Questions
Cannabis Europa 2026 dedicates multiple program segments to the German market—no accident. Germany has established itself as the regulatory anchor of Europe’s cannabis landscape: decisions made here ripple through supply chains, pricing, and product formats across the continent. Yet this influence is ambivalent. Medical cannabis imports grow on one hand; flower bulk prices collapse while EU-GMP premium formats gain traction on the other. This divergence receives dedicated panel discussion at the London conference: what strategies remain for producers and pharmacies in a market splitting into two segments?
Telemedicine regulation also features prominently—whether video-based first consultations for cannabis prescriptions should remain permissible is being watched by other European nations as potential precedent. The structural imbalance in Cannabis Social Clubs completes the German picture: only approximately 40 licenses have been granted nationwide, while industry representatives estimate actual demand at around 13,000 associations. Learn more about market development in our overview of the global medical cannabis market 2026.
New Focus Areas: Women’s Health, Portugal, and the End of Flower?
Cannabis Europa 2026 sets thematic priorities beyond standard market debate. Women’s health receives a dedicated session for the first time: endometriosis, menopausal symptoms, and other chronic conditions where conventional medicine regularly falls short are treated as distinct therapeutic applications for medical cannabis. This transcends mere diversity consideration—it signals that Europe’s market seeks clinical depth rather than relying on broad patient volumes.
Geographically, Portugal and Denmark come into focus: despite regulatory turbulence, Portugal continues attracting interest as a production site, while Denmark increasingly gains credibility as a reliable supplier. German names appear on the exhibition floor too: Bavarian vaporizer manufacturer Storz and Bickel, Sanity Group, and Berlin-based Cantourage have confirmed presentations.
From Flower to Pharmaceutical: The Strategic Question Behind All Questions
Perhaps the most critical question Cannabis Europa 2026 will ask: is Europe’s market permanently abandoning dried flower? The trend toward standardized extracts, capsules, and oils with defined cannabinoid profiles is measurable. For producers, pharmacies, and investors, this carries significant strategic consequences: those betting on cheap flower volumes today risk sitting in a shrinking market segment tomorrow.
Early investors in EU-GMP premium formats bear higher upfront costs but address the growing segment. Recently, the ICBC Berlin 2026, held mid-April, showed how seriously the industry is already pursuing these debates. London will advance them further—on a market in its decisive phase.
Frequently Asked Questions
What is Cannabis Europa?
Cannabis Europa is Europe’s leading B2B cannabis industry conference. It convenes regulatory bodies, investors, clinicians, and companies annually. In 2026, the event takes place May 26-27 at The Barbican in London.
How large is the European cannabis market in 2026?
According to Prohibition Partners, Europe’s legal medical cannabis market will exceed €1.5 billion for the first time in 2026. Germany is by far the continent’s largest single market.
What will be discussed at Cannabis Europa 2026?
The conference addresses the divergence between collapsing German flower bulk prices and growing EU-GMP premium formats, telemedicine regulation in Germany as a European model, cannabis and women’s health, and whether Europe’s market permanently shifts from flower toward pharmaceutical formats.
What’s the difference between flower and pharmaceutical formats?
Flower refers to dried cannabis buds that can be inhaled or brewed as tea. Pharmaceutical formats include standardized extracts, capsules, and oils with precisely defined cannabinoid composition. The latter offer physicians and patients greater dosing certainty but require more complex, expensive manufacturing.
When and where does Cannabis Europa 2026 take place?
Cannabis Europa 2026 occurs May 26-27, 2026 at The Barbican in London. The event features two days of main stage debates, expert panels, an expanded exhibition floor, and a VIP experience including the Business of Cannabis Awards.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
